Prior to launching Andrew Nava, LLC, I was a venture analyst, buy-side analyst, and most recently, the Director of Research at Actin Biomed, a New York-based healthcare investment firm where I was responsible for the medical, scientific and financial evaluation of potential private and public investments. I received my M.D. from the Johns Hopkins University School of Medicine and my B.S. in Biology from Cal Poly Pomona where I graduated summa cum laude. When I'm not absorbing everything about the healthcare markets and following 300+ companies, I like to hang out with my kids and cook for my wife.
Rocky spent time with Pfizer Global Research and Development and with Esperion Therapeutics before attending Columbia University to pursue a Ph.D. in organic chemistry. At Pfizer, Rocky worked in the Chemical Research and Development department working on early scale-up of potential drug molecule syntheses. At Esperion, he synthesized small peptide therapies for the treatment of atherosclerosis.
Rocky went on to receive his Ph.D. in organic chemistry from Columbia University. His thesis topic involved the development of several novel synthetic methodologies. He is currently a consultant in New York City.
“Development of a Formal [4+1] Cycloaddition: Pd(OAc)2-Catalyzed Intramolecular Cyclopropanation of 1,3-Dienyl β-Keto Esters and MgI2-Promoted Vinylcyclopropane-Cyclopentene Rearrangement”, Coscia, R. W.; Lambert, T. L. Journal of the American Chemical Society, 2009, 131, 2496-2498.
Follow me on Twitter: RockyBIP.
Disclaimer: I make every reasonable effort to make sure all data I present is factual. It is your responsibility to verify any data presented before making an investment decision. I generally do not include references to the data I present but I will provide them by request. Occasionally, errors in articles are caught after publication on Seeking Alpha and there's very little I can do to correct them in a timely manner. To see the most updated version of any article in the exact form I wished it to be presented please visit my website (www.biotechinvestmentparadigm.com).
Mike Havrilla is a former pharmacist, biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading service--please send me a direct message if you are interested in a discount promo code for 43% savings on a one-year subscription.